US 11,723,974 B2
Methods for treating digitally identified IL-4/IL-13-related disorders by administering an anti-IL4R-alpha antibody
Paul Bryce, Bridgewater, NJ (US); Emanuele De Rinaldis, Bridgewater, NJ (US); Ramon Antonio Hernandez Vecino, Paris (FR); Francisco Javier Jimenez Jimenez, Brookline, MA (US); and Cliona Marie Molony, Bridgewater, NJ (US)
Assigned to Sanofi-Aventis Biotechnology, Paris (FR)
Filed by Sanofi Biotechnology, Paris (FR)
Filed on Dec. 8, 2020, as Appl. No. 17/115,618.
Claims priority of provisional application 63/028,919, filed on May 22, 2020.
Claims priority of provisional application 62/945,807, filed on Dec. 9, 2019.
Claims priority of application No. 20315281 (EP), filed on Nov. 2, 2020; and application No. 20315450 (EP), filed on Nov. 13, 2020.
Prior Publication US 2021/0220470 A1, Jul. 22, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); G06N 20/00 (2019.01); A61K 31/137 (2006.01); A61K 31/522 (2006.01); A61K 31/56 (2006.01); A61K 31/573 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 31/522 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); C07K 16/2866 (2013.01); G06N 20/00 (2019.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01)] 48 Claims
 
1. A method of treating a subject with an anti-interleukin-4 receptor alpha (anti-IL-4Rα) antibody, comprising administering a therapeutically effective amount of an anti-IL-4Rα antibody to a subject exhibiting at least one symptom of a disorder selected from the group consisting of an esophageal-related disorder, a lung-related disorder, a blood-related disorder, a gastrointestinal-related disorder, a kidney-related disorder, a prostate-related disorder, Kawasaki's disease, a thyroid-related disorder, a blood-vessel-related disorder, a pregnancy-related disorder, and a cancer,
wherein the anti-IL-4Rα antibody comprises:
a variable heavy chain CDR1 of SEQ ID NO:1 (GFTFRDYA);
a variable heavy chain CDR2 of SEQ ID NO:2 (ISGSGGNT);
a variable heavy chain CDR3 of SEQ ID NO:3 (AKDRLSITIRPRYYGLDV);
a variable light chain CDR1 of SEQ ID NO:4 (QSLLYSIGYNY);
a variable light chain CDR2 of SEQ ID NO:5 (LGS); and
a variable light chain CDR3 of SEQ ID NO:6 (MQALQTPYT).